Business Information
The group's principal activity is to develop, manufacture and market essure tm, an innovative and proprietary non-incisional permanent birth control device for women. The group's focus is to improve diagnostic and therapeutic procedures in gynecology. The products are designed to provide non-surgical approach and diagnostic procedures to treat infertility and related disorders. The group is currently focused on developing its selective tubal occlusion procedure system, which is a non-surgical approach to fallopian tube sterilization. This helps physicians to perform fallopian tube sterilization in an office setting without general anesthesia. The products of the group are marketed through distributors in Europe, Australia, Asia and Canada.
|
|
Name |
Title
|
Email
|
| Kathryn Tunstall | Chmn. | N/A | | Darrin Uecker | VP - Research & Development and Operations | N/A | | Edward Sinclair | VP - Clinical Research, Regulatory Affairs, Quality Assurance | N/A | | Gregory Lichtwardt | Exec. VP, Treasurer, CFO | N/A | | Lisa Pohmajevich | VP - Marketing | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 41,900 | (18,487) | | 2005 | 21,169 | (21,801) | | 2004 | 11,612 | (26,069)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
